Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Int J Audiol. 2019 Nov 18;59(3):219–223. doi: 10.1080/14992027.2019.1690170

Table 6.

Comparison of key pharmacokinetic measures in participants with and without hearing loss, treated with kanamycin for multidrug-resistant tuberculosis

Variable Hearing loss (n=84)* No hearing loss (n=18)* P value
AUC0–10 155.6 (127.3 to 212.1) 152.5 (121.2 to 168.2) 0.425
Cumulative AUC0–10 9450.9 (6541.3 to 12615.2) 7226.8 (4794.7 to 9885.0) 0.103
Average daily AUC0–10 639.2 |(450.9 to 689) 644.1 (477.6 to 666.7) 0.567
Cumulative dose (mg) 46625 (33687.5 to 59375) 41678 (27750 to 62500) 0.390
Average daily dose (mg) 639.2 (450.9 to 689.0) 644.1 (477.6 to 666.7) 0.568

Median is shown with interquartile range in brackets